Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339747 | 0.93 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL25301629 | 0.86 | GPR119 (0.46) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL30338644 | 0.84 | KDM4E (0.63) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL25294745 | 0.84 | KDM4E (0.63) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL16754906 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| Hydrochloric Acid SCHEMBL30338561 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| Hydrochloric Acid SCHEMBL25263828 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1HSD17B10HPGDLMNA | |
| SCHEMBL9461734 | 0.81 | DKK1 (0.50) | KDM4EALDH1A1HSD17B10HPGDCYP2C19 | |
| SCHEMBL18255216 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9571697 | 0.81 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | KDM4E 2270/4885ALDH1A1 2211/4885HSD17B10 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.